Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Permax: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Permax - General Information

A long-acting dopamine agonist which is effective in the treatment of Parkinson&

 

Pharmacology of Permax

Permax is an ergot derivative dopamine receptor agonist at both D1 and D2 receptor sites. Permax is 10 to 1,000 times more potent than bromocriptine on a milligram per milligram basis in various in vitro and in vivo test systems. Permax mesylate inhibits the secretion of prolactin in humans; it causes a transient rise in serum concentrations of growth hormone and a decrease in serum concentrations of luteinizing hormone. In Parkinson’s disease, pergolide mesylate is believed to exert its therapeutic effect by directly stimulating postsynaptic dopamine receptors in the nigrostriatal system.

 

Permax for patients

Patients and their families should be informed of the common adverse consequences of the use of pergolide mesylate and the risk of hypotension. Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy. Patients should be advised to notify their physician if they are breast feeding an infant.

 

Permax Interactions

Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); these agents may diminish the effectiveness of Permax. Because pergolide mesylate is approximately 90% bound to plasma proteins, caution should be exercised if pergolide mesylate is coadministered with other drugs known to affect protein binding.

 

Permax Contraindications

Pergolide mesylate is contraindicated in patients who are hypersensitive to this drug or other ergot derivatives.

 

Additional information about Permax

Permax Indication

Indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson's disease.

Mechanism Of Action
Permax is a potent dopamine receptor agonist. It directly stimulates post-synaptic dopamine receptors at both D1 and D2 receptor sites in the nigrostriatal system.
Generic Name
Pergolide
Synonyms
Pergolida [Inn-Spanish]; Pergolide Mesylate; Pergolide Methanesulfonate; Pergolidum [Inn-Latin]
Drug Category
Neuroprotective Agents; Antiparkinson Agents; Antidyskinetics; Dopamine Agonists; Central Nervous System Agents
Drug Type
Small Molecule; Approved
Other Brand Names containing Pergolide
Permax;
Absorption
Significant amount may be absorbed (evidence on bioavailability still lacking).
Toxicity (Overdose)
Oral, rat LD50: 15 mg/kg. Symptoms of overdose include nausea, vomiting, convulsions, decreased blood pressure, and CNS stimulation.
Protein Binding
90%
Biotransformation
Extensively hepatic.
Half Life
27 hours
Dosage Forms of Permax
Tablet Oral
Chemical Formula
C19H26N2S
Organisms Affected
Humans and other mammals